| 19630254 |
Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent |
Intellia Therapeutics, Inc. |
HASAN, KHALEDA B |
1636 |
§103DP |
Non-Final OA |
— |
Pending |
Mar 26, 2026 |
| 19571722 |
Lamotrigine Salts, Co-Crystals, and Compositions |
Azurity Pharmaceuticals Ireland Limited |
CHANDRAKUMAR, NIZAL S |
1625 |
§103§112Other |
Final Rejection |
— |
Pending |
Mar 19, 2026 |
| 19276658 |
Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA) |
Intellia Therapeutics, Inc. |
FAN, WEIHUA |
1663 |
DP |
Non-Final OA |
— |
Pending |
Jul 22, 2025 |
| 19100872 |
Reduction of Signs of Skin Aging |
Carbocode S.A. |
PACKARD, BENJAMIN J |
1612 |
§101§102§112DP |
Non-Final OA |
— |
Pending |
Feb 03, 2025 |
| 18881324 |
Oral Liposomal Formulations of Fasudil |
Woolsey Pharmaceuticals, Inc. |
KENYON, JOHN S |
1625 |
§102§103§112 |
Non-Final OA |
— |
Pending |
Jan 06, 2025 |
| 18955685 |
Methods for Preparing Mutant Plants |
Carlsberg A/S |
IBRAHIM, MEDINA AHMED |
1662 |
§112Other |
Non-Final OA |
— |
Pending |
Nov 21, 2024 |
| 18929289 |
CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof |
Vertex Pharmaceuticals Incorporated |
SPENCE, JENNIFER SUZANNE |
|
§103§112Other |
Non-Final OA |
— |
Pending |
Oct 28, 2024 |
| 18924880 |
Abuse-Deterrent Pharmaceutical Composition with Aversion Properties |
Aardvark Therapeutics Inc. |
AGGARWAL, SAHIL CHANDER |
1623 |
§102§103§112 |
Non-Final OA |
— |
Pending |
Oct 23, 2024 |
| 18904985 |
Materials and Methods for Treatment of Hemoglobinopathies |
Vertex Pharmaceuticals Incorporated |
SPENCE, JENNIFER SUZANNE |
1633 |
§102§103§112DP |
Non-Final OA |
— |
Pending |
Oct 02, 2024 |
| 18850107 |
Novel Salt of GLP-1 Receptor Agonist Compound, Preparation Method Thereof and Pharmaceutical Composition Comprising Thereof |
Ildong Pharmaceutical Co., Ltd. |
HUI, SAN MING R |
1627 |
§103 |
Non-Final OA |
— |
Pending |
Sep 24, 2024 |
| 18844546 |
Modulation of Protein Levels |
Carlsberg A/S |
KEOGH, MATTHEW R |
1663 |
§102§103 |
Final Rejection |
60d |
Pending |
Sep 06, 2024 |
| 18792984 |
CD33-Binding Polypeptides and Uses Thereof |
Inhibrx Biosciences, Inc. |
ROONEY, NORA MAUREEN |
1641 |
§112Other |
Non-Final OA |
— |
Pending |
Aug 02, 2024 |
| 18782817 |
Method for Using Gene Expression to Determine Prognosis of Prostate Cancer |
Mdxhealth SA |
HANEY, AMANDA MARIE |
1682 |
§101§103§112 |
Non-Final OA |
— |
Pending |
Jul 24, 2024 |
| 18728193 |
DETECTION AND LOCALIZATION OF INTERNAL BLEEDING |
Cumberland Emerging Technologies, Inc. |
LEWOCZKO, EVAN MICHAEL |
1612 |
§103 |
Non-Final OA |
— |
Pending |
Jul 11, 2024 |
| 18724529 |
Altering the Optical Properties of Fibres |
Commonwealth Scientific And Industrial Research Organisation |
KRUSE, DAVID H |
1663 |
§102§103§112 |
Non-Final OA |
— |
Pending |
Jun 26, 2024 |
| 18739986 |
AAV Vectors |
Vigeneron GmbH |
BLUMEL, BENJAMIN P |
1671 |
§112 |
Final Rejection |
— |
Pending |
Jun 11, 2024 |
| 18716404 |
Uses of Bicyclic Compounds for the Treatment of Diseases |
Leonabio, Inc. |
COPPINS, JANET L |
1628 |
§103§112DP |
Non-Final OA |
— |
Pending |
Jun 04, 2024 |
| 18710370 |
Formulations and Methods for Treating Symptoms of Menopause |
Kindra Corporation |
OLSON, ANDREA STEFFEL |
1693 |
§102§103§112DP |
Non-Final OA |
— |
Pending |
May 15, 2024 |
| 18640699 |
Parabacteroides Goldsteinii to Treat or Prevent Inflammatory and AutoImmune Diseases |
Joslin Diabetes Center |
DEVI, SARVAMANGALA |
1645 |
§102§112 |
Non-Final OA |
— |
Pending |
Apr 19, 2024 |
| 18702733 |
CONDITION-ACTIVATABLE NUCLEIC ACID CONSTRUCTS AND THEIR USES FOR TREATING NEUROLOGICAL DISEASES |
Switch Therapeutics Inc. |
YU, DAVID TUYANG |
1635 |
§103§112DP |
Non-Final OA |
— |
Pending |
Apr 18, 2024 |
| 18631587 |
Monohydrate Salt of Denatonium Acetate |
Aardvark Therapeutics, Inc. |
OH, TAYLOR V |
1625 |
§102§103 |
Final Rejection |
— |
Pending |
Apr 10, 2024 |
| 18611364 |
ST2 ANTIGEN BINDING PROTEINS |
Amgen, Inc. |
MCCOLLUM, ANDREA K |
1674 |
§101§112Other |
Non-Final OA |
— |
Pending |
Mar 20, 2024 |
| 18606338 |
Methods of Using Donor-Derived Cell-Free DNA to Distinguish Acute Rejection and Other Conditions in Liver Transplant Recipients |
Northwestern University |
SWITZER, JULIET CAROLINE |
1682 |
§101§102§103§112 |
Final Rejection |
— |
Pending |
Mar 15, 2024 |
| 18683006 |
2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists |
Breye Therapeutics Aps |
HASTINGS, ALISON AZAR |
1627 |
§103§112 |
Final Rejection |
— |
Pending |
Feb 12, 2024 |
| 18435117 |
Compounds and Compositions for Selective Degradation of Engineered Proteins |
Bristol-Myers Squibb Company |
ISMAIL, REHANA |
1625 |
§102§103§112 |
Non-Final OA |
— |
Pending |
Feb 07, 2024 |
| 18434621 |
CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS |
Rayzebio, Inc. |
MOSHER, ERIC PARKER |
1612 |
§101§102§103§112DP |
Non-Final OA |
— |
Pending |
Feb 06, 2024 |
| 18431646 |
CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR KRAS G12C PROTEINS |
Rayzebio, Inc. |
MEJIAS, SAMANTHA LEE |
1618 |
§103§112 |
Non-Final OA |
— |
Pending |
Feb 02, 2024 |
| 18431656 |
CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS |
Rayzebio, Inc. |
DONOHUE, SEAN R |
1618 |
§102§103DP |
Non-Final OA |
— |
Pending |
Feb 02, 2024 |
| 18423804 |
Methods, Systems, and Compositions for Diagnosing Transplant Rejection |
The Scripps Research Institute |
JONES, CHRISTINE MICHELLE |
1682 |
§101§103§112DP |
Non-Final OA |
— |
Pending |
Jan 26, 2024 |
| 18579943 |
Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders |
Tim Therapeutics, Inc. |
PIPIC, ALMA |
1617 |
§103 |
Final Rejection |
53d |
Pending |
Jan 17, 2024 |
| 18577414 |
Fetal Mesenchymal Stem Cells |
Boost Pharma Aps |
WESTON, ALYSSA G |
1633 |
§101§102§103 |
Final Rejection |
— |
Pending |
Jan 08, 2024 |
| 18513964 |
Methods for Reducing Risk of Onset of Acute Graft Versus Host Disease After Hematopoeitic Cell Transplantation |
Csl Behring LLC |
BEANE, RANDALL L |
1654 |
§103 |
Final Rejection |
70d |
Pending |
Nov 20, 2023 |
| 18511869 |
USE OF HER2-TARGETING ANTIBODY-DRUG CONJUGATE IN TREATMENT OF HER2-LOW EXPRESSING BREAST CANCER |
Remegen Co., Ltd. |
BUCCINI, MICHELLE CALLAHAN |
1675 |
§103§112DP |
Non-Final OA |
— |
Pending |
Nov 16, 2023 |
| 18510979 |
Therapeutic Microvesicles of Probiotic Bacteria |
BIOGAIA AB |
HINES, JANA A |
1645 |
§103 |
Non-Final OA |
— |
Pending |
Nov 16, 2023 |
| 18507778 |
Compositions and Methods for Targeting Cancer Stem Cells |
The General Hospital Corporation |
COOK, LISA V |
1642 |
§103§112DP |
Non-Final OA |
— |
Pending |
Nov 13, 2023 |
| 18557182 |
COMBINATION OF BITTER RECEPTOR AGONIST AND GUT-SIGNALING COMPOUND |
Aardvark Therapeutics, Inc. |
HIBBERT, CATHERINE S |
1658 |
§102§103§112 |
Non-Final OA |
— |
Pending |
Oct 25, 2023 |
| 18279612 |
Compositions and Methods For Reducing Immune Intolerance |
Tim Therapeutics, Inc. |
KIM, YUNSOO |
1641 |
§112Other |
Non-Final OA |
— |
Pending |
Aug 31, 2023 |
| 18456269 |
Compositions and Methods for Treatment of Myotonic Dystrophy Type 1 with CRISPR/SACAS9 |
Vertex Pharmaceuticals Incorporated |
VIJAYARAGHAVAN, JAGAMYA NMN |
1633 |
§103§112Other |
Non-Final OA |
— |
Pending |
Aug 25, 2023 |
| 18450966 |
USE OF ANTIBODY-DRUG CONJUGATE TARGETING HER2 IN TREATMENT OF SPECIFIC BREAST CANCER |
Remegen Co., Ltd. |
PUTTLITZ, KARL J |
1646 |
§103DP |
Final Rejection |
— |
Pending |
Aug 16, 2023 |
| 18546155 |
Methods for Treating Multiple Myeloma |
Celgene Corporation |
BENAVIDES, JENNIFER ANN |
1675 |
§101§103 |
Non-Final OA |
— |
Pending |
Aug 11, 2023 |
| 18264475 |
Formulations of DR5 Binding Polypeptides |
Inhibrx Biosciences, Inc. |
CESARE, JOSEPH DAVID |
1675 |
§112Other |
Non-Final OA |
5d |
Pending |
Aug 07, 2023 |
| 18275254 |
Danegaptide for Use in the Treatment or Prevention of a Kidney Disease |
Breye Therapeutics Aps |
MCMILLIAN, KARA RENITA |
1623 |
§103 |
Final Rejection |
— |
Pending |
Aug 01, 2023 |
| 18339930 |
Compositions and Methods for Genetically Modifying CIITA in a Cell |
Intellia Therapeutics, Inc. |
SMALL, KATHERINE R |
1633 |
§102§112 |
Non-Final OA |
— |
Pending |
Jun 22, 2023 |
| 18339665 |
Compositions and Methods for Reducing HLA-A in a Cell |
Intellia Therapeutics, Inc. |
SPENCER, ANDREA LYNNE MORRIS |
1631 |
§103§112 |
Non-Final OA |
— |
Pending |
Jun 22, 2023 |
| 18332335 |
Polynucleotides, Compositions, and Methods for Genome Editing Involving Deamination |
Intellia Therapeutics, Inc. |
REGA, KYLE THOMAS |
1636 |
§102§103§112 |
Non-Final OA |
— |
Pending |
Jun 09, 2023 |
| 18332390 |
Compositions and Methods for Reducing MHC Class II in a Cell |
Intellia Therapeutics, Inc. |
KIM, TAEYOON |
1631 |
§102§103§112 |
Non-Final OA |
— |
Pending |
Jun 09, 2023 |
| 18265063 |
Aldehyde Dehydrogenase Inhibitors and Their Therapeutic Use |
Cancer Research Technology Limited |
HASTINGS, ALISON AZAR |
1627 |
§103 |
Non-Final OA |
— |
Pending |
Jun 02, 2023 |
| 18323488 |
Methods and Treatment for Complex Lymphatic Malformations |
Avalo, Inc. |
KOSTURKO, GEORGE W |
1621 |
§103 |
Final Rejection |
49d overdue |
Pending |
May 25, 2023 |
| 18253485 |
Method for Treating Antibody-Mediated Rejection |
Csl Behring GmbH |
HIBBERT, CATHERINE S |
1658 |
§103§112DP |
Final Rejection |
— |
Pending |
May 18, 2023 |
| 18248079 |
CD19-Directed Chimeric Antigen Receptor Constructs |
Sorrento Therapeutics, Inc. |
HAMA, JOANNE |
1647 |
§103§112 |
Final Rejection |
104d overdue |
Pending |
Apr 06, 2023 |
| 18070908 |
Compositions Derived from Placenta and Methods of Producing the Same |
StimLabs, LLC |
JOHNSON, KARA D |
1632 |
§102DP |
Final Rejection |
5d |
Pending |
Nov 29, 2022 |
| 18050333 |
Methods of in Vitro Cell Delivery |
Intellia Therapeutics, Inc. |
ZHU, JIANJIAN |
1631 |
§103Other |
Final Rejection |
6d |
Pending |
Oct 27, 2022 |
| 17921128 |
Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus |
Avm Biotechnology, LLC |
HAVLIN, ROBERT H |
1626 |
§103§112Other |
Final Rejection |
23d overdue |
Pending |
Oct 25, 2022 |
| 17801293 |
Lymphocyte Population and Methods for Producing Same |
Avm Biotechnology, LLC |
CHICKS, ASHLI ARIANA |
1626 |
§103Other |
Final Rejection |
27d |
Pending |
Aug 22, 2022 |
| 17845399 |
Pharmaceutical Composition for Treatment or Prevention of Multiple Inflammatory disorders |
Aardvark Therapeutics, Inc. |
IVANOVA, SVETLANA M |
1627 |
§103 |
Non-Final OA |
60d overdue |
Pending |
Jun 21, 2022 |
| 17836265 |
Modified Guide RNAs for Gene Editing |
Intellia Therapeutics, Inc. |
ARIETI, RUTH SOPHIA |
1635 |
§102§103§112Other |
Final Rejection |
30d overdue |
Pending |
Jun 09, 2022 |
| 17824450 |
DISTANCE DOMINANT INTRAOCULAR LENS |
Bausch & Lomb Incorporated |
RIOS, GABRIELLA GISELLE BONO |
3774 |
§103 |
Non-Final OA |
— |
Pending |
May 25, 2022 |
| 17777402 |
Processes for the Preparation of Alpha-Hydroxy Esters via Grignard Coupling and Thiolation Reactions |
Kemin Industries, Inc. |
CARR, DEBORAH D |
1691 |
§112 |
Non-Final OA |
72d overdue |
Pending |
May 17, 2022 |
| 17735929 |
Methods and Compositions for Directed Genome Editing |
Intellia Therapeutics, Inc. |
HASAN, KHALEDA B |
1636 |
§103§112DP |
Non-Final OA |
— |
Pending |
May 03, 2022 |
| 17637410 |
BLOOD GENE BIOMARKERS TO DIAGNOSE AND PREDICT ACUTE REJECTION IN LIVER TRANSPLANT RECIPIENTS |
Northwestern University |
MYERS, CARLA J |
1682 |
§101§102§103§112 |
Non-Final OA |
2d overdue |
Pending |
Feb 22, 2022 |
| 17542712 |
Replacement of Cytotoxic Preconditioning Before Cellular Immunotherapy |
Avm Biotechnology, LLC |
SANG, HONG |
1646 |
§112 |
Final Rejection |
14d |
Pending |
Dec 06, 2021 |
| 17532363 |
URINE BIOMARKERS |
Exosome Diagnostics, Inc. |
POHNERT, STEVEN C |
1683 |
§101§103§112DP |
Final Rejection |
— |
Pending |
Nov 22, 2021 |
| 17612074 |
Substituted 4-[5-(Benzofuran-2-yl)-1,2,4-Oxadiazol-3-yl]Benzoic Acid Compounds for Use in Therapy for Neuropathic Pain |
King'S College London |
DAHLIN, HEATHER RAQUEL |
1629 |
§103DP |
Final Rejection |
12d |
Pending |
Nov 17, 2021 |
| 17469665 |
Compositions and Methods for Treatment of Duchenne Muscular Dystrophy |
Vertex Pharmaceuticals Incorporated |
TATGE, LEXUS MARC |
1637 |
§103DP |
Non-Final OA |
— |
Pending |
Sep 08, 2021 |
| 17418458 |
Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof |
Inhibrx Biosciences, Inc. |
EDGINGTONGIORDANO, FRANCESCA |
1643 |
§103Other |
Non-Final OA |
66d overdue |
Pending |
Jun 25, 2021 |
| 17111769 |
Modified Guide RNAs for Gene Editing |
Intellia Therapeutics, Inc. |
PENNINGTON, KATIE LEIGH |
1634 |
Other |
Non-Final OA |
17d overdue |
Pending |
Dec 04, 2020 |
| 17107203 |
VEGFR-2 TARGETING DNA VACCINE FOR COMBINATION THERAPY |
Vaximm AG |
DEVI, SARVAMANGALA |
1645 |
DP |
Final Rejection |
— |
Pending |
Nov 30, 2020 |
| 15550951 |
MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES |
William Marsh Rice University |
CANDELARIA, JULIANA IRENE |
1600 |
§103DP |
Final Rejection |
— |
Pending |
Aug 14, 2017 |
